Indication
Congenital Nephrogenic Diabetes Insipidus
1 clinical trial
1 product
Clinical trial
A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1)Status: Recruiting, Estimated PCD: 2025-09-30
Product
PB